10-Q Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 Q3 2018

Filing Information

Form Type	10-Q
Accession Number	`0001532176-18-000036`
Period End Date	20180930
Filing Date	20181106
Fiscal Year	2018
Fiscal Period	Q3
XBRL Instance	regn-20180930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 63 Income Statement 76 Cash Flow Statement 58

Balance Sheet 63 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred stock, issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$792.07M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$812.73M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.09B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$1.10B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$596.85M	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.54B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.67B	USD	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$193.68M	USD	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$269.27M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$267.94M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$242.01M	USD	Point-in-time
Treasury stock, outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Treasury stock, outstanding (in shares)	`TreasuryStockShares`	3.99M	shares	Point-in-time
Inventories	`InventoryNet`	$1.04B	USD	Point-in-time
Inventories	`InventoryNet`	$726.14M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$284.81M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$224.97M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$5.72B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.34B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$1.87B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$1.49B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.36B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.52B	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$562.82M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$506.29M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$125.20M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$77.87M	USD	Point-in-time
Total assets	`Assets`	$10.81B	USD	Point-in-time
Total assets	`Assets`	$8.76B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$178.18M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$172.36M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$637.16M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$781.92M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.42B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.14B	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$703.45M	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$707.20M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$152.07M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$194.03M	USD	Point-in-time
Total liabilities	`Liabilities`	$2.62B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.94B	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.84B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.51B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$2.95B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$4.43B	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-10.52M	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$640.00K	USD	Point-in-time
Treasury Stock, at cost; 3,990,021 shares in 2018 and 3,763,868 shares in 2017	`TreasuryStockValue`	$396.37M	USD	Point-in-time
Treasury Stock, at cost; 3,990,021 shares in 2018 and 3,763,868 shares in 2017	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$7.87B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.14B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$8.76B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$10.81B	USD	Point-in-time

Income Statement 76 line items

Line Item	Tag	Value	Unit	Period
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.78B	USD	3 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.66B	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.50B	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.29B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$529.75M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.55B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$556.97M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.58B	USD	3 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$306.77M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$910.52M	USD	3 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$369.23M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$1.06B	USD	3 Qtrs
Total expenses	`CostsAndExpenses`	$1.04B	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$2.75B	USD	3 Qtrs
Total expenses	`CostsAndExpenses`	$940.75M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$2.97B	USD	3 Qtrs
Income from operations	`OperatingIncomeLoss`	$1.82B	USD	3 Qtrs
Income from operations	`OperatingIncomeLoss`	$626.92M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$1.54B	USD	3 Qtrs
Income from operations	`OperatingIncomeLoss`	$559.93M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$16.43M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$2.05M	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$81.84M	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$11.86M	USD	1 Quarter
Interest expense	`InterestExpense`	$19.08M	USD	3 Qtrs
Interest expense	`InterestExpense`	$20.85M	USD	3 Qtrs
Interest expense	`InterestExpense`	$6.18M	USD	1 Quarter
Interest expense	`InterestExpense`	$7.49M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$8.94M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$5.68M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$-17.04M	USD	3 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$60.99M	USD	3 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$565.61M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$635.86M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.88B	USD	3 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.52B	USD	3 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$41.21M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$177.29M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$498.75M	USD	3 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$253.29M	USD	3 Qtrs
Net income	`NetIncomeLoss`	$388.32M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.62B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$594.65M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.02B	USD	3 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$9.66	USD	3 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$15.06	USD	3 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$3.64	USD	1 Quarter
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$5.50	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$5.17	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$14.14	USD	3 Qtrs
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$3.32	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$8.84	USD	3 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	107.83M	shares	3 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	106.71M	shares	1 Quarter
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	108.03M	shares	1 Quarter
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	106.11M	shares	3 Qtrs
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.09M	shares	1 Quarter
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.99M	shares	3 Qtrs
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.84M	shares	3 Qtrs
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	117.03M	shares	1 Quarter
Net income	`NetIncomeLoss`	$388.32M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.62B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$594.65M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.02B	USD	3 Qtrs
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$36.65M	USD	3 Qtrs
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$752.00K	USD	1 Quarter
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$21.48M	USD	1 Quarter
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-6.95M	USD	3 Qtrs
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$30.00K	USD	3 Qtrs
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$341.00K	USD	1 Quarter
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$2.00K	USD	1 Quarter
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$2.39M	USD	3 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$1.06B	USD	3 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$1.62B	USD	3 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$409.80M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$595.75M	USD	1 Quarter

Cash Flow Statement 58 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$388.32M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.62B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$594.65M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.02B	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$105.44M	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$110.96M	USD	3 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$300.65M	USD	3 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$380.14M	USD	3 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$-44.02M	USD	3 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$82.69M	USD	3 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$108.24M	USD	3 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$33.52M	USD	3 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$359.83M	USD	3 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$228.60M	USD	3 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$235.65M	USD	3 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$281.62M	USD	3 Qtrs
Increase in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$28.21M	USD	3 Qtrs
Increase in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$87.82M	USD	3 Qtrs
Increase (decrease) in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-59.12M	USD	3 Qtrs
Increase (decrease) in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-29.46M	USD	3 Qtrs
Increase (decrease) in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$179.85M	USD	3 Qtrs
Increase (decrease) in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-28.91M	USD	3 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-157.78M	USD	3 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-284.83M	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.47B	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$740.16M	USD	3 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$883.75M	USD	3 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$1.53B	USD	3 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$379.27M	USD	3 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$644.10M	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$164.96M	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$297.64M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	-	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$10.00M	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.20B	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-669.44M	USD	3 Qtrs
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$57.00M	USD	3 Qtrs
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	-	USD	3 Qtrs
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebtAndCapitalSecurities`	-	USD	3 Qtrs
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebtAndCapitalSecurities`	$19.93M	USD	3 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$226.89M	USD	3 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$87.41M	USD	3 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$77.10M	USD	3 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$77.83M	USD	3 Qtrs
Repurchases of Common Stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	3 Qtrs
Repurchases of Common Stock	`PaymentsForRepurchaseOfCommonStock`	$4.38M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$186.13M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.93M	USD	3 Qtrs
Net increase in cash, cash equivalents, and restricted cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$256.86M	USD	3 Qtrs
Net increase in cash, cash equivalents, and restricted cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$275.11M	USD	3 Qtrs
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.10B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$547.70M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$804.57M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$825.23M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.10B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$547.70M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$804.57M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$825.23M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.